KalVista Pharmaceuticals (KALV) Change in Account Payables (2014 - 2025)

KalVista Pharmaceuticals has disclosed Change in Account Payables across 12 years of filings, most recently posting $2.5 million for Q3 2025.

• Change in Account Payables for Q3 2025 came in at $2.5 million, up 67.11% year-over-year; the trailing twelve-month figure through Jul 2025 was -$3.2 million (down 156.7% YoY), and the FY2025 annual result was -$5.0 million, down 215.07% from the prior year.
• Change in Account Payables came in at $2.5 million for Q3 2025 at KalVista Pharmaceuticals, up from -$1.4 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $6.1 million in Q2 2024 to a low of -$5.9 million in Q4 2024.
• The 5-year median for Change in Account Payables is $81500.0 (2023), against an average of $198777.8.
• Peak annual rise in Change in Account Payables reached 1290.74% in 2024, while the deepest fall reached 10754.55% in 2024.
• KalVista Pharmaceuticals' Change in Account Payables stood at $1.7 million in 2021, then slumped by 64.7% to $597000.0 in 2022, then sank by 90.79% to $55000.0 in 2023, then plunged by 10754.55% to -$5.9 million in 2024, then surged by 142.83% to $2.5 million in 2025.
• The last three Change in Account Payables figures came in at $2.5 million (Q3 2025), -$1.4 million (Q2 2025), and -$5.9 million (Q4 2024), per Business Quant data.